Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

tyrosine kinase inhibitor (TKI) being evaluated as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations. The U.S. Food and Drug Administration (FDA ...

What Does The Future Look Like For HER2 Inhibitors Market ... along with effective management of drug resistance and global market penetration, are pivotal drivers of this anticipated growth.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...